Feb 27, 2025 · Endevica’s novel peptidomimetics overcome the current limitations of small molecules, antibodies and other modalities to treat conditions safely, effectively and with …

Endevica Bio currently has two assets: a clinical-stage drug for cancer cachexia that is entering P2 trials in 2025, and an advanced preclinical therapeutic for obesity that shows efficacy in …

Discover Endevica Bio's rapidly-growing pipeline of GPCR-targeting peptides for unmet high-value medical needs. Explore cutting-edge solutions today.

Endevica Bio | 1,884 followers on LinkedIn. Reversing cachexia and improving quality of life in cancer patients.

Mar 30, 2021 · COLUMBIA, Mo.-- (BUSINESS WIRE)--Tensive Controls Inc. (TCI Peptide Therapeutics), a company developing best-in-class peptide drug candidates with better safety …

June 16-19, 2025 Boston Convention & Exhibition CenterMenu

© BIO 2024 All Rights Reserved Privacy Policy Terms Of Use

Endevica Bio's primary pharmaceutical product is a peptide therapy designed to address cachexia resulting from cancer and various persistent illnesses.

Apr 23, 2024 · Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity …

Reach out to Endevica Bio at our Northbrook address or email [email protected]. Contact us for inquiries or support.